A local hospital is taking part in a study involving a new type of topical antibiotic; one that's even showing promise in treating so-called super bugs.
Many different strains of certain diseases are becoming resistant to conventional antibiotics.
Some of the so called super bugs such as MRSA are spreading because there are very few drugs that can stop it.
However, a new topical drug may be the answer and you could be a part of the study.
Dr. Frederick Epstein is the medical director for the Emergency Department at Bay Medical.
He is the only so called "investigator" in this area for a new type of topical antibiotic called Scrape.
"Scrape is a new study that's being conducted by Glaxo in an effort to bring a new drug to the market," Dr. Epstein said.
If you want to be a part of this study, the primary eligibility criteria is you need what is considered a minor laceration or wound that has become infected.
"As long as they are approximately 10 cm or 4 inches in length or what we call 2% body surface area. The palm of your hand is one percent of body surface area. So, relatively small or contained wound and the key is they have to show clinical evidence of infection," Dr. Epstein explained.
The wound can't have come from an animal bite or human bite; patients have to be at least 2-months-old and pregnant or breast feeding women are not eligible.
"It is a study and the study has a control, which means the tube of ointment that they are given, two out of three of these tubes will be actual study drugs,” Dr. Epstein continued. “One out of three of the drugs are actually the vehicle with no antibiotic in it."
If you choose to take part in the study, the safe guard is you are closely monitored.
"We call you the very next day to check on the wound to find out if you're not responding,” Dr. Epstein said, reassuringly. “We would withdraw you from the study promptly and put them on a conventional antibiotic."
Patients will get a backpack with all the dressing materials required to go along with the antibiotics; it has to be applied twice daily for five days.
The only other obligation is keeping a journal of the times of day and the number of days the antibiotic was applied.
Patients will get a check-up four times in nine days, so there's very little chance something could go wrong.
However, there's more exciting news about Scrape.
Dr. Epstein explains, "The potential excitement about the drug is that it may be affective against some of these super bugs that have been much discussed in the media the last few years and have become virtually epidemic in ordinary wound infection."
That includes the tough to treat super bug MRSA.
Scrape is already approved for use in Europe and has been proven affective against MRSA.
For more information on Scrape, call Bay Medical.